Key result
Among Indonesian post-PCI patients on ticagrelor, 40% exhibited low on-treatment platelet reactivity (LTPR) and 5% exhibited high on-treatment platelet reactivity (HTPR).
Why the study?
Altered on-treatment platelet reactivity with P2Y12 inhibitors is linked to bleeding or ischemic events after PCI, prompting mapping of platelet response to ticagrelor in Indonesian patients.
What is the prevalence of low or high on-treatment platelet reactivity in Indonesian post-PCI patients receiving ticagrelor?
Cross-Sectional (n=20)
No
What is the prevalence of low or high on-treatment platelet reactivity in Indonesian post-PCI patients receiving ticagrelor?
A significant proportion of Indonesian post-PCI patients on ticagrelor exhibit low on-treatment platelet reactivity, suggesting a potential role for de-escalation strategies to prevent bleeding.
Answers are grounded in this paper and cite their sources.
High LTPR prevalence on ticagrelor in Indonesians may signal bleeding risk; leaves open outcome correlations and personalized therapy trials.
Background: Low on-treatment platelet reactivity (LTPR) or High on-treatment platelet reactivity (HTPR) with P2Y12 inhibitors is associated with bleeding (LTPR) or ischemic events (HTPR) in patients on dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI). Objective: Mapping of Indonesian patients’ platelet response secondary to ticagrelor and thus identifying either LTPR or HTPR. Method: During May – June 2019, 20 post-PCI patients on aspirin–ticagrelor combination were included. Light transmission aggregometry (LTA) for monitoring platelet function was used. Ticagrelor’s LTA <40% is LTPR while >70% is HTPR. Result: Patients were mostly male (18 patients) and aged between 40-73 years old with a history of diabetes and/or hypertension and smoking. About eight patients (40%) were LTPR and one (5%) patient was HTPR. Conclusion: A personalised DAPT strategy for preventing bleeding events, a de-escalation, might be valuable for Indonesian patients.
No takes yet. Share an insight, caveat, or question.
Zulkarnain et al. (2023) conducted a cross-sectional in Acute coronary syndrome post-percutaneous coronary intervention (n=20). Ticagrelor was evaluated on Platelet reactivity status (LTPR, normal response, HTPR) measured by light transmission aggregometry (LTA). Among Indonesian post-PCI patients on ticagrelor, 40% exhibited low on-treatment platelet reactivity (LTPR) and 5% exhibited high on-treatment platelet reactivity (HTPR).
Synapse has enriched 10 related papers. Consider them for comparative context: